AsedaSciences has developed an AI driven platform that transforms the relationship between chemical structure and biological effect into high value predictive information for rapid decision making. We are constantly looking for opportunities to collaborate in ways that demonstrate the value that such transformation creates. If you have ideas for a potential collaboration, partnership or publication that you feel would be of benefit to the scientific community, please contact us.
To discuss joint publication opportunities, contact us.Contact Us
Bieberich et al, SLAS, February 2017Download
Bieberich et al, Nature Scientific Reports, July 2022Download
CIO Review, November 2021Download
Bieberich et al, Journal of Pharmacological and Toxicological Methods, June 2021Download
Bieberich et al, SOT, March 2022Download
St. Mary et al, SOT, March 2022Download
Prarthana et al. International Journal of Molecular Sciences, 2019Link
Knecht et al. Toxicology and Applied Pharmacology, 2017Link
Truong et al. Toxicological Sciences, January 2014Link
Tanguay et al. Archives of Toxicology, 2016Link
Hagstrom et al. Toxicological Sciences, January 2019Link
Truong et al. Journal of Hazardous Materials. June 2022Link
“This innovative technology can quickly assess a compound's inherent ability to cause acute cellular stress, which often leads to toxicity. Based on multiple retrospective analyses on hundreds of preclinical compounds and marketed drugs, along with discontinued and boxed warning drugs, the AsedaSciences methodology accurately predicted agents with higher toxicity risks. Thus, the predictions provide drug hunters with data to allow prioritization of the most promising compounds for progression into higher investment pharmacology and safety studies.
The results also show alignment with some human-specific safety risks, which may not manifest prior to human exposures. Given the capability of fast turnaround times, iterative SAR work to improve the safety profile of potential drug candidates seems a particularly impactful application in hit to lead and lead optimization campaigns. This important new tool will no doubt lead to significant time savings and productivity enhancements in drug discovery.”
"AsedaSciences has developed a much-needed platform that will provide medicinal chemists with actionable biologically relevant knowledge during all stages of lead optimization - the user interface is clear and has flexible functionality that will help chemists review, analyze and select compounds for progression in a very timely and straightforward manner. I predict that this will become an indispensable tool on a chemist's desktop. The user interface looks great and I would use this tool in a heartbeat"
“AsedaSciencesgoes beyond a toxicity screen—they have developed a reproducible, high-contentcellular screening system that allows for an evaluation of cellular andmetabolic stress. Simple ‘live/dead’ cellular health assays have limitedutility because the result is binary.
By examining cell metabolic/physiologic responses to xenobiotics with the AsedaSciences approach, one can start to tease out secondary/unintended targets and also understand whether these effects might be adverse or actually beneficial. This is an information-rich system that chemists will want to use to try and understand how a compound perturbs various cellular processes.”
December 3, 2021
AsedaSciences awarded Most Promising Pharma and Life Sciences Solution Provider 2021 by CIO Review
AsedaSciences was featured in a special edition of CIO Review and was named in the annual listing of Top 10 companies that are at the forefront of providing Pharma andLife Sciences solutions and transforming businesses. The feature was titled “Combining Data Quality and AI to Transform Drug Discovery”
Innovations Showcased AsedaSciences® forits Breakthroughs in Flow Cytometry, Aired via Discovery
AsedaSciences was featured on the September 2016 edition of the award-winning TV series, Innovations with Ed Begley Jr, which aired on the Discovery Channel.